This clinical evidence suggests that in metastatic patients TIM-3 can act as a marker of exhaustion in NK cells, thus supporting the role of TIM-3 blocking mAbs in reinvigorating anti-tumor immunity. Here, HAVCR2 is linked to neoplasm.